Robert W. Gergen Joins RPS as Vice President of Sales to Lead U.S. Sales Initiatives

Share Article

Rapid Pathogen Screening, Inc. (RPS®) today announced that Robert W. Gergen has joined RPS as Vice President of Sales.

Rapid Pathogen Screening, Inc. (RPS®) today announced that Robert W. Gergen has joined RPS as Vice President of Sales.

“Bob brings to RPS an impressive depth of experience, strong business relationships, and extensive knowledge of the primary care physician market – the key target market for current and future RPS products. He is an extremely effective and experienced leader with a proven record of successfully building technical selling teams in the rapid POC test market,” said Thomas Orsini, RPS's Chief Commercial Officer. "Bob’s leadership skills and industry acumen will position RPS to establish and significantly grow our national sales division as we launch the new AdenoPlus™ test for Adenoviral conjunctivitis in the U.S. this fall."

Gergen has nearly 24 years of successful sales and marketing experience in the medical diagnostic industry and point-of-care (POC) test market. Prior to joining RPS, Gergen served in various sales leadership roles at Quidel Corporation, most recently at the helm of the sales department, serving as its Director of North American Sales since 2005.

Under Gergen's leadership, Quidel’s U.S. sales experienced exponential growth from $50 million to $100 million during a three-year period. This growth resulted in Quidel achieving the number one market share position for sales of infectious disease POC diagnostic tests into the primary care market.

Gergen began his career as a sales representative for Johnson & Johnson Professional Diagnostics, and then went on to sell surgical lasers for use in operating rooms for Sun Medical, Inc. His additional positions focused on national and corporate accounts as well as distributor relations, which is of critical importance in penetrating the primary care market.

“It’s an exciting time to be joining RPS, with the company’s pipeline of novel POC tests,” said Gergen. "RPS is well-positioned for growth and I look forward to positively impacting the commercialization of new products and next generation technologies, as we create a paradigm shift in how diseases in this country are accurately diagnosed and thus effectively treated.”

Gergen earned his BA in Education from Oklahoma City University.

About RPS
Founded in 2004, Rapid Pathogen Screening, Inc. (RPS) is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to rapidly identify patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being used to develop tests for bio-terrorism and chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment. For more information on RPS or its products, visit

# # #

For additional information, contact:
Laura Lovejoy, RPS Director of Strategic Marketing, 941.556.1864, lovejoy(at)rpsdetectors(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Laura Lovejoy
Rapid Pathogen Screening, Inc. (RPS)
(941) 556-1864
Email >
Visit website